New Year’s Eve, everything is updated! Public information shows that the financing atmosphere in the domestic biopharmaceutical and high-end medical equipment fields has continued to be hot recently!

The enterprises that have obtained financing cover a wide range of high prosperity sub sectors, including non-invasive brain computer interfaces, protein degradation, high-end scientific instruments, nuclear coupled drugs, AI precision diagnosis and treatment, intraoperative imaging, traditional Chinese medicine achievement transformation, molecular gel degradation agents, organ regeneration, invasive brain computer interfaces, nuclear receptors and GPCR innovative drugs, etc. These enterprises promote the comprehensive advancement of China’s biopharmaceutical industry chain from source innovation to clinical implementation and industrial upgrading, and help domestic innovative drugs and high-end medical equipment achieve high-quality development.

1、 Kongshan Ci Technology completes Pre-A round of financing to accelerate clinical translation of brain computer interaction neural regulation platform

Recently, Shanghai Kongshan Ci Technology Co., Ltd. (hereinafter referred to as “Kongshan Ci Technology”) officially announced the completion of the Pre-A round of financing. This round of financing is exclusively led by Yunqi Capital, and the raised funds will focus on core technology iteration, clinical translation promotion, and global layout expansion, consolidating the company’s leading position in the field of non-invasive brain computer interfaces and neural regulation.
Kongshan Ci Technology focuses on the clinical needs of neuroscience and builds a new generation of fully stacked brain computer interactive neural regulation technology platform. Its core advantage lies in the deep integration of multidimensional brain signal analysis technology with multiple regulation methods such as ultrasound, magnetic, electrical, and optical. At the same time, it embeds AI algorithms throughout the entire process of diagnosis, treatment, and management, forming a closed-loop iterative system of “clinical data accumulation intervention plan optimization”, providing systematic and precise solutions for the diagnosis and treatment of brain functional diseases.
At the clinical translation level, the company has established a deep scientific research collaboration with the National Center for Psychiatry, achieving breakthrough results in early clinical exploration and significantly improving patient symptoms in a short period of time. Its technical efficacy is outstanding in the field of non-invasive brain computer interfaces, and related technological achievements have received attention and recognition from top overseas universities.
It is reported that the company is following the implementation path of “scientific research clinical family” and is building a diversified product matrix. The landing of this financing demonstrates the high recognition of the capital market for its technological barriers, clinical value, and commercial potential. In the future, Kongshan Ci Technology will accelerate the transformation of technology into clinical practice and strive to build a globally leading intelligent infrastructure platform for neuroscience.

2、 Pudiri completes angel+round financing, breaking through CNS and difficult to drug targets for inflammation through a multi mechanism platform
Focusing on the field of central nervous system (CNS) and inflammatory diseases, Prodegre Pharmaceuticals recently announced the completion of tens of millions of yuan in angel+round financing. This round of financing is led by Sanfu Fund (Fudan University Student Medical Conversion Fund under FuRong Investment), with the core team of the company providing follow-up support, injecting momentum into the research and development of its innovative protein degradation platform and pipeline promotion.
As a platform based biotechnology enterprise, Pudiri takes multi mechanism drive as its core and independently builds Prodegre ATLAS ™ The differentiated protein degradation and interaction platform differs from traditional technologies that rely on a single route and E3 ligase. Through an AI empowered integrated research and development process, it achieves an upgrade from screening to rational design of degradation agents, greatly expanding the range of accessible targets.
Its core technology covers three major pathways: peptide degradation agents, small molecule degradation agents, and new E3 ligands. Among them, PDR-001, as the world’s first only in class peptide degradation drug to enter the clinical stage, can accurately target difficult to drug targets such as alpha synuclein. This round of financing will focus on promoting IND application for the pipeline, optimizing oral dosage forms, and platform iteration.
Academician Wang Yutian (founder and chairman of the company) and the head of Sanfu Fund, Li Zhengxiong, both stated that Pudirui’s differentiated technology strategy has significant industrial value and is expected to break through the bottleneck of global difficult to drug target research and development. In the future, it will accelerate technology transformation and create a benchmark for innovative drug research and development in the CNS and inflammation fields.

3、 Konomi has received tens of millions of yuan in investment from the Beijing Municipal Government’s guidance fund, leading the domestic high-end liquid chromatography industry
Under the guidance of the national policy of independent high-end equipment scientific instruments, the localization process of high-end liquid chromatography, as the core basic equipment for scientific research and innovation, has attracted much attention. Recently, Chromai (Beijing) Technology Co., Ltd. completed a new round of strategic financing worth tens of millions of yuan, exclusively funded by the Beijing Medical and Health Industry Investment Fund, to help the company deepen its core technology research and development and industrial layout.
Founded in 2019, Konomi is one of the few domestic enterprises that can independently develop ultra-high performance liquid chromatography systems from core components to complete machines. It has built a full chain innovation system covering hardware, software, and customized services, and its core product performance has reached the international advanced level.
Its products are widely used in multiple fields due to their 22000 PSI ultra-high pressure resistance design, diversified feature configurations, and AI enabled data processing systems, which are compatible with GMP and GLP compliance requirements. This financing will focus on R&D iteration, capacity optimization, and market expansion, demonstrating the government’s recognition of domestic high-end scientific instrument innovation.
In the future, with the support of this funding, Konomi will continue to break through technological barriers, expand domestic and international markets, consolidate its leading position in the domestic high-end liquid chromatography field, assist in the high-quality development of China’s scientific instrument industry, and promote the breakthrough of “Made in China” in the global market.

4、 Fan Enke has completed a Series B financing of over 100 million yuan, accelerating the construction of an innovative nuclear drug research and development platform

Radioisotope coupled drugs (RDCs), as the core track of precision medicine, have become a new growth pole in the biopharmaceutical industry with the advantage of integrated diagnosis and treatment, and the global market is experiencing rapid expansion. Recently, Fan Enke Biotechnology (Zhongshan) Co., Ltd., which focuses on RDC research and development, announced the completion of over 100 million yuan in Series B financing, injecting strong momentum into innovative nuclear drug research and clinical translation.
This round of financing is led by a well-known investment institution and Hecheng Capital, with follow-up investment from institutions such as Fengyang Jialu and Zhongshan Jianzhuo. Old stocks Dongsheng Lianxing and Renxi Fund continue to increase their investment. As an innovative enterprise focusing on precision treatment of tumors, Fanenkole relies on the InnoRDC platform with independent intellectual property rights and 30 years of research and development accumulation of the team to achieve “high tumor enrichment and fast kidney clearance” of drugs, building a differentiated technical barrier.
At present, the company has 5 products entering the IIT clinical stage, and has completed nearly 100 clinical studies on cancer patients, with significant research and development conversion results. The funds raised this time will be mainly used for upgrading the nuclear drug research and development platform and promoting clinical pipelines. Founder Dr. Xi Ning stated that this round of financing demonstrates the recognition of the capital market for the company’s technological path. In the future, Fanenkole will continue to deepen its involvement in the RDC field, accelerate the clinical verification of core pipelines, create innovative nuclear drug varieties with global competitiveness, and support the development of the precision medicine industry.

5、 Xuanyan Biotechnology has completed tens of millions of yuan in Pre-A round financing, focusing on the landing and iteration of AI precision diagnosis and treatment products

Shanghai Xuanyan Biotechnology recently announced the completion of a Pre-A round of financing worth tens of millions of yuan, invested by DeTong Capital. The funds raised will focus on clinical validation, registration and application, and large-scale application of core products, fully promoting the development of AI driven precision diagnosis and treatment products from research and development to clinical practice, and bridging the “last mile” of scientific research achievement transformation.
As a platform based enterprise, Xuanyan Biotechnology relies on its self-developed “integrated omics+AI” big data analysis platform to deeply cultivate unmet clinical decision-making needs. Its core team has strong capabilities and provides solid technical support for product development and implementation, focusing on the dual track of AI assisted diagnosis and drug research and development.
In terms of product layout, the company has launched its core landing product – thyroid cancer lymph node metastasis detection kit, equipped with AI assisted evaluation software. Currently, it has initiated a special review process for innovative medical devices, and is simultaneously promoting CE certification and FDA-BDD innovation channel application. It has also been clinically applied in multiple provinces and cities; At the same time, multiple diagnosis and treatment pipelines such as esophageal cancer and urothelial cancer will be arranged, and innovative target research and development in fields such as advanced recurrent bladder cancer will be promoted in parallel. This financing demonstrates the recognition of the clinical value and technological barriers of its products by the capital market. In the future, Xuanyan Biotechnology will continue to focus on products, deepen technological integration, accelerate product landing and pipeline expansion, participate in industry standard setting, and help the digital upgrading of the precision diagnosis and treatment industry.

6、 Yiying Medical has completed a B+round financing of over 100 million yuan, leading the market share of 3D C-arm in the field of smart surgery
Recently, Jiangsu Yiying Medical Equipment Co., Ltd. announced the completion of a B+round financing of over 100 million yuan. The investment team for this round is strong, including Chuanfa Hongke Fund, SoftBank Xinchuang, Jushi Venture Capital, Nantong Investment Management, and Heavy Industries Asset Management, among others. The raised funds will focus on promoting the market of intelligent intraoperative imaging equipment, while accelerating the research and development of digital consumables products, further consolidating the company’s leading position in the field of smart surgery. The current demand in the field of intraoperative imaging continues to increase, with the 3D C-arm track growing rapidly, with a year-on-year increase of over 110%, becoming a core growth point in the field of intraoperative imaging.
As a leading enterprise in digital surgical solutions, Yiying Medical focuses on the digitalization of surgical technology, breaking through the limitations of traditional imaging equipment and creating a closed-loop solution of “equipment+AI+ecology”. The company’s core layout includes 5 series of products, including 3D C-arm and O-arm CT. With core advantages such as lightweight design, low radiation, and 5S fast scanning, it flexibly adapts to multi department surgical scenarios. Currently, it has served over 200 clinical hospitals and departments across the country, allowing grassroots patients to enjoy millimeter level precision treatment.
This financing demonstrates the recognition of the capital market for its technological strength and market potential. In the future, Yiying Medical will deepen the integration of intraoperative imaging and AI technology, promote the evolution of products towards “seeing clearly” and “understanding clearly”, practice the concept of “high-end diagnosis and treatment, widely accessible”, and help upgrade the smart surgery industry.

7、 The Chinese Medical Association has received investment from the Shunyi Tianzhu government to accelerate the regional layout of the transformation of traditional Chinese medicine achievements
Recently, Beijing Guoyi Medical Union Health Technology Co., Ltd. received investment from the Beijing Guomen Tongxiang Equity Investment Fund, which was established under the leadership of the Tianzhu government in Shunyi District, Beijing. The company’s valuation in this round reached 200 million yuan. This strategic investment will focus on supporting the China Medical Association in deepening the construction of the clinical formula transformation system for traditional Chinese medicine in Shunyi District, and working together to build a demonstration center for the transformation of traditional Chinese medicine achievements based in India and radiating throughout the country.
As a high-tech enterprise focusing on the transformation of traditional Chinese medicine achievements, the China Medical Association relies on authoritative research institutions and renowned traditional Chinese medicine resources to form significant technological advantages in the field of transdermal drug delivery. Its independently developed TCM external treatment carrier technology and supporting instruments have served nearly 10000 hospitals across the country. Its core project has won Series A financing from Tongrentang Fund, and its technology and commercial potential have been recognized by the market.
This cooperation is in line with the health industry plan of Shunyi District, marking a crucial step for the China Medical Association in policy coordination and regional resource integration. In the future, the company will rely on the integrated system of “technology+operation+channel” to accelerate the large-scale application of clinical achievements in traditional Chinese medicine, and help promote the innovation of traditional Chinese medicine and the high-quality development of regional industries.

8、 Sanofi makes a $30 million strategic equity investment in GeBo Biotech to advance the research and development of sickle cell disease molecular gels
Recently, clinical stage biotechnology company GeBo Biotechnology announced that it has received a strategic equity investment of $30 million from Sanofi. This round of funding will focus on the research and development of core projects GLB-005 and GLB-007, both of which are expected to become disease modifying therapies for sickle cell disease. The first phase of clinical research will begin as early as the end of 2026.
According to the agreement between the two parties, Sanofi has subscribed to the newly issued preferred shares of Gebo Biotechnology and obtained the priority negotiation rights for research, development, and commercialization related to two core projects. As a pioneer in the field of molecular gel degradation agents, GeBo Biotech relies on proprietary GDD technology © The platform has established an integrated research and development system, with core pipelines GLB-005 and GLB-007 providing oral treatment options for patients by degrading fetal hemoglobin inhibitory factors.
Established in 2021, GeBo Biotech has previously received investments from multiple institutions such as Hillhouse Venture Capital and Qiming Venture Capital, and currently has two pipelines in the Phase I clinical stage. This strategic investment by Sanofi demonstrates its recognition of GeBo Biotechnology’s strength and pipeline potential. Both parties will work together to promote the implementation of innovative therapies for sickle cell disease and fill the unmet clinical needs.

9、 Jimei Ruisheng has completed a Series C financing of 350 million yuan, leading the innovative development of organ regeneration medicine

Recently, Regend Therapeutics Limited, a leading enterprise in the field of organ regeneration medicine, announced the completion of a RMB 350 million Series C financing. In this round, 7 well-known institutions including Yuzhe Capital, Hefei Gaotou, and Hongtai Fund have been newly introduced, and 5 old shareholders including Shanshuixi Capital and Tianshili Capital have continued to increase their investments. The raised funds will be mainly used for the clinical promotion of core precursor cell products, deepening IND applications, and building a commercial system.
Founded in 2015, Jimei Rui Sheng is a leading global enterprise in the research and development of organ function regeneration therapy and industrial integration. It focuses on the three high demand tracks of chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF), and chronic kidney disease (CKD), relying on the advantage of targeted tissue regeneration of precursor cells to break through the traditional bottleneck of treating chronic diseases that are difficult to cure. Its technological route is in line with the regulatory guidance of advanced therapeutic drugs (ATMP) in China.
In terms of pipeline layout, REGEND001 focuses on alveolar regeneration to address the clinical pain points of irreversible alveolar injury in COPD and IPF patients; REGEND003, as the first renal precursor cell therapy approved by NMPA IND in China, uses non-invasive urine derived cells to achieve nephron regeneration. It has initiated Phase I clinical trials and received support from the National Key Research and Development Program. This financing demonstrates the capital market’s recognition of its precursor cell technology barriers and pipeline clinical value, and will continue to lead the innovation and upgrading of the organ regeneration medical industry in the future.

10、 Half a year of consecutive two rounds of financing! Zhiran Medical has completed a 300 million yuan A+round financing, leading the domestic invasive brain computer interface race
Recently, Zhiran Medical, a leading domestic enterprise in invasive brain computer interfaces, announced the completion of a 300 million yuan A+round of financing. This round is led by Zhongke Chuangxing, with joint investment from more than ten school shareholders including Junlian Capital, IDG Capital, and Sequoia China. It is reported that this is the second round of financing completed by the company within six months, with a cumulative financing amount of 600 million yuan, demonstrating the high recognition of its technological strength and track potential by the capital market. The raised funds will be mainly used for the promotion of large-scale clinical trials and the iteration of high-throughput flexible brain computer interface products.
As a benchmark enterprise for domestic invasive brain computer interfaces, Zhiran Medical firmly lays out the path of invasive technology. Different from the shortcomings of semi invasive signal resolution, its technology can accurately capture single neuron action potentials (Spikes) with high spatial resolution, and has an order of magnitude advantage in information transmission speed. It benchmarks Neuralink in global competition and builds a barrier to independent innovation throughout the entire chain.
The company has overcome four core technology bases, including flexible electrodes and neural chips. Its stretchable high-throughput flexible electrodes have solved industry pain points, and the results have been published in Nature Electronics; The power consumption of domestically produced neural signal acquisition chips has been reduced by 75%, and the matching implanted robots have connected the “last mile” of clinical implementation. At present, the first clinical implantation of over 100 channel products in China has been completed, and it is planned to launch large-scale registered clinical trials in 2026 to help China achieve global leadership in this field.

11. Kaisikadi completed a series of financing of nearly 500 million yuan to deeply explore the research and development of innovative drugs for nuclear receptors and GPCRs

Recently, Shanghai Kaisikai Di announced the completion of a new round of financing worth nearly 500 million yuan. This round was led by Zhongping Capital, with joint participation from multiple institutions including Guoshou Capital, Qingsong Capital, and Qingdao Guoxin. The previous round’s lead investor, Guotou Xianxian, as well as existing shareholders Gaorong Venture Capital and Kangjun Capital, continued to invest additional funds. This financing sets a new record for the company’s single financing amount, demonstrating the capital market’s high recognition of its technological strength and pipeline potential. As an innovative drug research and development enterprise focusing on metabolic diseases, Kaisikai Di takes the original innovation of nuclear receptor and GPCR targeted drugs as its core, relying on its original technological advantage of “structure-based drug design”. It has deepened its research and development in metabolic-related conditions such as Metabolic Associated Steatohepatitis (MASH) and Primary Biliary Cholangitis (PBC). The core research and development team has more than 20 years of research and development experience in related fields, possessing first-class new drug research and development capabilities.
The funds raised in this round will primarily be used to advance the global multicenter Phase III clinical trials and global registrations of the initial product pipeline. Simultaneously, the company will expand its research pipeline matrix, aiming to develop potential Best-in-Class/First-in-Class therapies in the field of metabolic diseases. Its core product, CS0159, possesses the potential to achieve Best-in-Class breakthroughs. Currently, the company has established a diverse pipeline of Class I new drugs. In the future, it will continue to address unmet clinical needs in metabolic diseases and foster global competitiveness for domestically produced innovative drugs.

About Us

MeritsIP: Your Global Intellectual Property Partner

At MeritsIP, we provide comprehensive IP services in biomedicine, medical devices, manufacturing, semiconductors, and AI. We support 200+ top clients globally with strategic, high-quality IP services.

Stay Connected

• • Website: https://www.meritsipglobal.com

• • LinkedIn: Follow us on LinkedIn

• • Email: info@meritsip.com

© 2025 MeritsIP. All Rights Reserved.